Breast Cancer Treatment in as Little as 1 Day
IORT | Intraoperative Radiation Therapy
Explore an Innovative Approach to Breast Cancer Treatment
We are passionate about targeted cancer care expertly tailored to meet patients’ personalized needs. We designed the Xoft® Axxent® Electronic Brachytherapy (eBx®) System® to empower physicians with full confidence to precisely and effectively treat cancer and enable their patients to live healthy, high-quality lives.
Xoft offers patients and physicians a simplified alternative to traditional six-week radiation therapy for early-stage breast cancer treatment. Our commitment to this innovative technology is driven by the unique and valuable benefits it offers to physicians, facilities, and patients.
What is Breast IORT?
Breast IORT is an advanced, patient-friendly radiation treatment option. With IORT, a complete, concentrated dose of radiation is delivered in one treatment during surgery. Traditional external beam radiation therapy (EBRT) involves daily radiation treatments for six to eight weeks. This may result in patients electing a mastectomy rather than breast-conserving surgery, or failing to comply with follow-up treatment.
IORT can be delivered in one day. IORT uses a miniaturized x-ray source to deliver a full course of targeted radiation directly within the tumor cavity where the cancer is most likely to recur, carefully destroying cancer cells and reducing the risk of damage to nearby healthy tissue including the heart, lungs, and ribs.1 This helps reduce potential side effects which are more common with whole breast irradiation.2 With IORT, radiation therapy can be adapted to the personalized needs of the patient.
A clinical breakthrough for breast cancer treatment
Targeted
A miniaturized x-ray source delivers a precise dose of radiation directly to the tumor site, the area with the highest risk of recurrence, immediately following surgery.
$
Reduced costs
By streamlining the delivery of radiation therapy, IORT offers a cost-effective solution for both physicians and patients.3
Efficient
IORT with the Xoft System is delivered at the time of surgery, offering a simple, 1-day treatment solution and improved quality of life for appropriately selected patients.
Versatile
IORT may be utilized to deliver a single fraction or boost dose. IORT boost may allow for reduction of subsequent traditional radiation therapy by approximately one week.
100% of patients in a clinical study were very pleased with the Xoft breast IORT treatment experience and outcome on follow up visits.4
What Clinicians are Saying:
Dr. Olga Ivanov, Florida Hospital Celebration Health, discusses the clinical value of Xoft IORT.
Learn More>
The Xoft System is FDA cleared, CE marked and licensed in a growing number of countries for the treatment of cancer anywhere in the body. It is supported by a growing body of evidence for the treatment of early-stage breast cancer, non-melanoma skin cancer (NMSC), gynecological cancers and brain cancers.
Emerging applications include prostate, pancreatic, and colorectal. Our commitment to this innovative technology is driven by the valuable benefits it offers to physicians, facilities and patients.
Discover our core line of Breast eBx products
Learn More>
Axxent Controller
The Xoft System is FDA cleared, CE marked, and licensed in a growing number of countries for the treatment of cancer anywhere in the body.
Balloon Applicators
The Axxent balloon applicators are a key component of the Xoft System, empowering targeted delivery of intracavitary and intraoperative radiation therapy.
Rigid Shield
The Axxent Rigid Shield is an optional component of the Xoft System utilized when additional protection of tissue or organs from radiation is desired.
References: 1. Dickler, et al. “A Dosimetric comparison of MammoSite high dose rate brachytherapy and Xoft Axxent electronic brachytherapy,” Brachytherapy (6) 2007, 164–168. 2. Epstein M, et al. Acute and Chronic Complications in Breast Cancer Patients Treated with Intraoperative Radiation Therapy. Ann Surg Oncol. 2016 Oct;23(10):3304-9. 3. Patel R, Ivanov O, Voigt J. Lifetime cost-effectiveness analysis of intraoperative radiation therapy versus external beam radiation therapy for early stage breast cancer. Cost Effectiveness and Resource Allocation : C/E. 2017;15:22. doi:10.1186/s12962-017-0084-5. 4. Proulx G. Intraoperative Radiation (IORT) as Adjuvant Radiation Monotherapy for Early-Stage Breast Cancer Patients Treated with Breast Conserving Surgery. Presented at the American Brachytherapy Society Annual Meeting 2017.
Products
Resources
Precision therapy. Personalized care.
© Xoft, a subsidiary of iCAD, Inc. All rights reserved. Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.